Abstract
Since their discovery, TNF alpha inhibitors significantly changed the therapeutic approach to immune-mediated inflammatory diseases, including rheumatoid arthritis. On the other hand, biological therapy became very expensive with pronounced impact on the budget of insurance companies.
Therefore, the introduction of biosimilars into clinical practice has been further another crucial step. Their main goal is to reduce treatment expenses and improve the availability of the biologics.
One of the most widespread molecule is adalimumab. Currently, 4 biosimilars from this group are available in the Czech Republic.
The efficacy and safety of Hyrimoz(R) has been proven in patients with plaque type of psoriasis (ADACCESS trial) as well as in the group of patients with rheumatoid arthritis (ADMYRA trial).